These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis. Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267 [No Abstract] [Full Text] [Related]
11. Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer. Demark-Wahnefried W; Rais-Bahrami S; Desmond RA; Gordetsky JB; Hunter GR; Yang ES; Azrad M; Frugé AD; Tsuruta Y; Norian LA; Segal R; Grizzle WE Br J Cancer; 2017 Oct; 117(9):1303-1313. PubMed ID: 28881355 [TBL] [Abstract][Full Text] [Related]
12. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675 [TBL] [Abstract][Full Text] [Related]
13. [Development of promising biomarkers for prostate cancer]. Yoneyama T; Ohyama C Nihon Rinsho; 2016 May; 74 Suppl 3():191-5. PubMed ID: 27344727 [No Abstract] [Full Text] [Related]
14. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer. Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474 [TBL] [Abstract][Full Text] [Related]
15. Combined detection of cancer cells and a tumor biomarker using an immunomagnetic sensor for the improvement of prostate-cancer diagnosis. Yang HW; Lin CW; Hua MY; Liao SS; Chen YT; Chen HC; Weng WH; Chuang CK; Pang ST; Ma CC Adv Mater; 2014 Jun; 26(22):3662-6. PubMed ID: 24648414 [No Abstract] [Full Text] [Related]
16. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers. Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048 [TBL] [Abstract][Full Text] [Related]
17. New circulating tumor cell technology could advance personalized medicine in prostate cancer. Miller S Nanomedicine (Lond); 2013 May; 8(5):683-4. PubMed ID: 23656263 [No Abstract] [Full Text] [Related]
18. [Circulating tumor cells: a real time dive into malignant plasticity]. Lopresti A; Acquaviva C; Birnbaum D; Mamessier É Med Sci (Paris); 2017 May; 33(5):491-493. PubMed ID: 28612723 [No Abstract] [Full Text] [Related]
19. Biomarkers and prostate cancer progression. Fillon M J Natl Cancer Inst; 2011 Nov; 103(21):1570-1. PubMed ID: 22010173 [No Abstract] [Full Text] [Related]